Related trials
JUPITER, 2008 - rosuvastatin vs placebo
Song, 2008 - vs
SAGE, 2007 - atorvastatin high dose vs pravastatin
METEOR, 2007 - rosuvastatin vs placebo
CORONA, 2007 - rosuvastatin vs placebo
Chello et al., 2006 - preoperative atorvastatin vs placebo
ASPEN, 2006 - atorvastatin vs placebo
SPARCL, 2006 - atorvastatin vs placebo
Patti et al., 2006 - preoperative atorvastatin vs placebo
MEGA, 2006 - pravastatin vs control
IDEAL, 2005 - atorvastatin high dose vs simvastatin
Vascular basis, 2005 - atorvastatin high dose vs lovastatin
TNT, 2005 - atorvastatin high dose vs atorvastatin
PACT, 2004 - pravastatin vs placebo
A to Z, 2004 - simvastatin vs placebo
ESTABLISH, 2004 - atorvastatin vs usual care
REVERSAL, 2004 - atorvastatin high dose vs pravastatin
HPS (sub groups), 2004 - simvastatin vs placebo
CARDS, 2004 - atorvastatin vs placebo
PACT, 2004 - pravastatin vs placebo
ASCOT, 2003 - atorvastatin vs placebo
LIPS (sub groups), 2002 - fluvastatin vs placebo
ALLHAT, 2002 - pravastatin vs usual care
PTT, 2002 - pravastatin vs usual care
PROSPER, 2002 - pravastatin vs placebo
See also:
All CABG surgery clinical trials
All clinical trials of cholesterol lowering intervention
All clinical trials of preoperative atorvastatin
|
|
Treatments
Studied treatment |
preoperative atorvastatin 20 mg/d, started 3 wks before surgery
|
Control treatment |
placebo
|
Patients
Method and design
Randomized effectives |
20 / 20 (studied vs. control) |
Blinding |
double blind |
Follow-up duration |
7 days |
Results
Endpoint
Studied treat. n/N
Control treat. n/N
Graph
RR [95% CI]
atrial fibrillation
2 / 20
5 / 20
0,40 [0,09;1,83]
myocardial infarction (fatal and non fatal)
0 / 20
0 / 20
classic
1,00 [0,00;246,89]
All cause death
0 / 20
0 / 20
classic
1,00 [0,00;246,89]
stroke (fatal and non fatal)
0 / 20
0 / 20
classic
1,00 [0,00;246,89]
0
2
1.0
Relative risks
|
Endpoint |
Events (%) |
Relative Risk |
95% CI |
Endpoint definition in the trial |
Ref |
Studied treat. |
Control treat. |
atrial fibrillation
|
2 / 20 (10,0%) |
5 / 20 (25,0%) |
0,40 |
[0,09;1,83] |
|
|
myocardial infarction (fatal and non fatal)
|
0 / 20 (2,5%) |
0 / 20 (2,5%) |
1,00 |
[0,02;47,98] |
|
|
All cause death
|
0 / 20 (2,5%) |
0 / 20 (2,5%) |
1,00 |
[0,02;47,98] |
|
|
stroke (fatal and non fatal)
|
0 / 20 (2,5%) |
0 / 20 (2,5%) |
1,00 |
[0,02;47,98] |
|
|
The primary endpoint (if exists) appears in blod characters
|
Reference(s) used for data extraction:
0:
|
Endpoint |
studied treat. |
control treat. |
mean diff |
Absolute risk reduction (for a follow-up of 7 days)
|
Endpoint |
Events rate |
Absolute risk reduction (ARR) |
Studied treat. |
Control treat. |
atrial fibrillation |
10,00% |
25,00% |
-15,00%
|
Meta-analysis of all similar trials:
cholesterol lowering intervention in CABG surgery for preoperative statins
Reference(s)
TrialResults-center ID |
TRC7245
|
Trials register # |
NA
|
-
Chello M, Patti G, Candura D, Mastrobuoni S, Di Sciascio G, Agrò F, Carassiti M, Covino E.
Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery..
Crit Care Med 2006;34:660-7
Pubmed
|
Hubmed
| Fulltext
|